Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expansion adds Scott Coward as Class I director through 2028 and Paul Kuznik as Class II director through 2029.
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expansion adds Scott Coward as Class I director through 2028 and Paul Kuznik as Class II director through 2029
- Coward joins Audit Committee, adding public-company governance, legal, M&A and integration expertise
- Kuznik joins Commercial Committee, adding medical-device commercialization, manufacturing and regulatory experience
- Each receives $50,000 annual cash retainer, $5,000 committee fee and option for 125,000 shares
- No disclosed director-selection arrangements or related-party interests under Item 404(a)
Item 7.01 · Regulation FD Disclosure
- Board appointments of Mr. Coward and Mr. Kuznik, signaling changes in Humacyte’s governance and strategic oversight
- Press release furnished as Exhibit 99.1, containing appointment details relevant to shareholder assessment
Item EX-99.1 · Exhibit EX-99.1
- Board additions target commercialization and global operations as Humacyte expands Symvess launch and prepares dialysis-access ATEV launch
- Scott Coward adds public-company governance, M&A integration, legal, and compliance expertise through Audit Committee appointment
- Paul Kuznik adds vascular-device commercialization, manufacturing, regulatory, quality, and physician-engagement expertise through Commercial Committee appointment
- ATEV remains FDA-approved only for extremity vascular trauma; dialysis access and PAD applications remain investigational
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.